QUANTUM GENOMICS SAS-REGR (ALQGC.PA)
FR0011648971 - Common Stock
ALQGC gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 73 industry peers in the Biotechnology industry. ALQGC has a bad profitability rating. Also its financial health evaluation is rather negative. ALQGC has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
ALQGC had negative earnings in the past year.
ALQGC had negative earnings in each of the past 5 years.
ALQGC had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ALQGC has a Return On Assets of -84.63%. This is in the lower half of the industry: ALQGC underperforms 76.47% of its industry peers.
Looking at the Return On Equity, with a value of -726.18%, ALQGC is doing worse than 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -84.63% | ||
| ROE | -726.18% | ||
| ROIC | N/A |
ROA(3y)-87.78%
ROA(5y)-71.29%
ROE(3y)-517.57%
ROE(5y)-335.54%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ALQGC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ALQGC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALQGC has about the same amount of shares outstanding.
ALQGC has more shares outstanding than it did 5 years ago.
ALQGC has a worse debt/assets ratio than last year.
2.2 Solvency
ALQGC has an Altman-Z score of -12.32. This is a bad value and indicates that ALQGC is not financially healthy and even has some risk of bankruptcy.
ALQGC has a Altman-Z score of -12.32. This is amonst the worse of the industry: ALQGC underperforms 85.29% of its industry peers.
A Debt/Equity ratio of 4.49 is on the high side and indicates that ALQGC has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 4.49, ALQGC is doing worse than 72.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.49 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -12.32 |
ROIC/WACCN/A
WACC6.54%
2.3 Liquidity
ALQGC has a Current Ratio of 2.73. This indicates that ALQGC is financially healthy and has no problem in meeting its short term obligations.
ALQGC has a Current ratio of 2.73. This is in the better half of the industry: ALQGC outperforms 61.76% of its industry peers.
ALQGC has a Quick Ratio of 2.73. This indicates that ALQGC is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ALQGC (2.73) is better than 61.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.73 | ||
| Quick Ratio | 2.73 |
3. Growth
3.1 Past
ALQGC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 87.28%, which is quite impressive.
The Revenue for ALQGC has decreased by -98.34% in the past year. This is quite bad
Measured over the past years, ALQGC shows a very negative growth in Revenue. The Revenue has been decreasing by -79.70% on average per year.
EPS 1Y (TTM)87.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.58%
Revenue 1Y (TTM)-98.34%
Revenue growth 3Y-79.7%
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y6121.43%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year1744.53%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
ALQGC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
ALQGC is valuated cheaply with a Price/Forward Earnings ratio of 0.00.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ALQGC indicates a rather cheap valuation: ALQGC is cheaper than 100.00% of the companies listed in the same industry.
ALQGC's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 21.99.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 0 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for ALQGC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
QUANTUM GENOMICS SAS-REGR
EPA:ALQGC (9/18/2024, 7:00:00 PM)
0.0155
+0 (+12.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.07M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 0 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -84.63% | ||
| ROE | -726.18% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.49 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.73 | ||
| Quick Ratio | 2.73 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)87.28%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y6121.43%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-98.34%
Revenue growth 3Y-79.7%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y